LiverAce™: Detect Liver Injury Earlier and with Greater Confidence
Go beyond the limitations of ALT/AST. Our LiverAce™ Research-Use-Only kits provide highly specific, mechanistically informative data for drug-induced liver injury (DILI) assessment, empowering researchers in pharma, biotech, and CROs to make better decisions, faster.
Early Detection
Identify hepatocellular injury hours before traditional ALT tests show a signal, enabling quicker intervention.
Superior Specificity
Leverage liver-specific miR-122 to eliminate false positives from muscle or other non-hepatic tissue damage.
Mechanistic Insight
Differentiate between apoptosis and necrosis via Keratin 18 to understand how injury occurs.
Immunoassay-like Protocol
Go from sample to result in under 5 hours with a PCR-free, no-extraction, direct detection protocol.
A Solution for Every Research Need
Whether you need rapid, specific screening or a deep, mechanistic profile, the LiverAce™ family has you covered.
LiverAce™ COMBO Kit
For comprehensive mechanistic insight, simultaneously measuring miR-122 and Keratin 18.
LiverAce™ SinglePlex Kit
For highly specific and rapid screening, focused on the gold-standard miR-122 biomarker.
The Destina Advantage: Our Technology
Our proprietary Dynamic Chemical Labelling (DCL) technology enables direct, quantitative, and PCR-free detection of nucleic acids, revolutionizing biomarker analysis.
Direct Detection. No Amplification. No Contamination.
Unlike PCR-based methods, our DCL chemistry bypasses the need for enzymatic reactions, reverse transcription, and amplification. This eliminates associated biases, reduces hands-on time, and drastically cuts the time to result.
-
✓
PCR-Free: Avoids amplification errors and bias for more accurate quantification.
-
✓
Rapid Turnaround: Delivers results in under 5 hours, accelerating your research.
-
✓
Multiplex Capable: Simultaneously detect RNA (miR-122) and protein (K18) from a single sample with the COMBO kit.
-
✓
Robust & Stable: Our proprietary Stabiltech™ buffer protects RNA integrity in biological fluids, ensuring reliable results.
Simple, Streamlined, Superior
1. Add Sample
2. Hybridize
3. Label
4. Read
| Feature | Traditional Methods |
LiverAce™ COMBO |
|---|---|---|
| Time to Result | Days | < 5 Hours |
| Sample Handling | Split Samples | One Sample |
| Workflow | Complex | Streamlined |
| Quantification | Relative | Absolute |
| Lab Requirement | Multiple Labs | Single Lab |
Data-Driven Insights
Visually understand the superior performance and biological rationale behind our LiverAce™ biomarkers.
Biomarker Rise After Insult
Adapted from: Chowdhary V et al.. Am J Pathol. 2017 Dec;187(12):2758-2774.
Resources & Publications
User Guides (Protocols)
Download the complete, detailed protocols for the LiverAce™ kits.
Key Publications (Biomarkers)
Clinical evidence supporting miR-122 and Keratin-18 as superior biomarkers for drug-induced liver injury.
Key Publications (LiverAce™ on Luminex platforms)
Foundational papers on the Dynamic Chemical Labelling (DCL) technology that powers LiverAce™ assays on Luminex platforms.
Ready to Transform Your Liver Safety Assessment?
Contact our specialists to discuss your research needs, request a quote, or inquire about our free evaluation kits.
Contact Us
For inquiries, quotes, or to request an evaluation kit, please email us at: